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a b s t r a c t
Several cellular transcription factors have been shown to be involved in IE62-mediated activation. The
YY1 cellular transcription factor has activating and repressive effects on gene transcription. Analysis of
the VZV genome revealed 19 postulated YY1 binding sites located within putative promoters of 16 VZV
genes. Electrophoretic mobility shift assays (EMSA) conﬁrmed the binding of YY1 to ORF10, ORF28/29
and gI promoters and the mutation of these binding sites inhibited YY1 binding and the promoter
activation by IE62 alone or following VZV infection. Mutation of the ORF28/29 YY1 site in the VZV
genome displayed insigniﬁcant inﬂuence on virus growth in melanoma cells; but it inhibited the virus
replication signiﬁcantly at day 5 and 6 post infection in HELF cells. This work suggests a novel role for the
cellular factor YY1 in VZV replication through the mediation of IE62 activation of viral gene expression.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Varicella-zoster virus (VZV) is a neurotropic herpesvirus and
member of the family alphaherpesvirinae. It causes two diseases,
varicella (chickenpox) during primary infection and herpes zoster
(shingles) upon reactivation from latency in sensory ganglia. The
VZV genome consists of a 125 kb linear double-stranded DNA
molecule that encodes at least 71 genes (Cohen et al., 2007). All of
the VZV genes are believed to be expressed during lytic infection
in three kinetic classes, immediate early (IE), early and late. Like
other herpesviruses, VZV uses the host cell RNA polymerase II
(RNA Pol II) and the general transcription apparatus of the cell for
viral gene transcription. A few VZV proteins, including IE62, IE4,
ORF61, IE63 and ORF10 are responsible for efﬁcient viral gene
expression (Cohen et al., 2007). IE62, the primary viral transacti-
vator, regulates the expression of genes from all three putative
kinetic classes (Kinchington et al., 2000).
Several cellular transcription factors have been shown to be
involved in the regulation of VZV gene expression mediated by
IE62. Sp1 family members target the GC rich sequence within VZV
promoters and interact with IE62 (Peng et al., 2003; Ruyechan
et al., 2003). The presence of a GC rich sequence that binds Sp1 has
been found in gE, gI and ORF28/29 promoters (Beraraducci et al.,
2007; Peng et al., 2003; Yang et al., 2004). Sp1 and Sp3 bind to the
downstream region of VZV oriS and to the ORF3 promoter;
mutation of their binding sites inhibited ORF62, ORF63 and ORF3
expression in reporter gene assays (Khalil et al., 2012, 2013).
The upstream sequence factor, USF, is another cellular factor
involved in IE62-mediated gene expression (Rahaus et al., 2003).
The USF consensus binding sequence (5′-CACGTG-3′) is present in
some VZV promoters and IE62 interacts with USF (Rahaus et al.,
2003). The ORF10 and ORF28/29 promoter sequences have USF
sites and mutation of these sites inhibited gene expression in
reporter gene assays (Che et al., 2007; Yang et al., 2004, 2006).
Yang et al., (2008) showed that the human mediator complex is
also an essential component for efﬁcient VZV gene expression. The
physical interaction between the N-terminal acidic activation
domain (TAD) of IE62 and the factors involved in the formation
of the human mediator complex has been demonstrated (Yang
et al., 2008; Yamamoto et al., 2009).
Other classes of mammalian transcription factors have been
identiﬁed but their role in transcriptional regulation is not well
understood. Yin Yang1 or YY1 is a cellular transcription factor
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discovered about 22 years ago (Shi et al., 1991). YY1 belongs to the
GLI-Kruppel class of zinc ﬁnger proteins that are ubiquitously
expressed and play an important role in biological processes such
as embryogenesis, differentiation, replication and cellular prolif-
eration (Yang et al., 1995; Gordon et al., 2006). The YY1 protein
contains four C2H2 type zinc ﬁnger domains near the C-terminal
half of the protein responsible for the DNA binding activity and
two acidic activation domains near the N-terminal half that are
capable of transcriptional activation (Hyde-DeRuyscher et al.,
1995; Yant et al., 1995). YY1 protein is responsible for activating
or repressing a diverse group of promoters depending on the
promoter architecture, which is the origin of the name Yin Yang
(Shi et al., 1991). YY1 has also been shown to interact with other
cellular factors including Sp1, Histone deacetylase2, ATF6 and
Notch1 (Seto et al., 1993; Yao et al., 2001; Li et al., 2000; Yeh
et al., 2003).
Two YY1 protein consensus binding sites were identiﬁed
recently in the VZV genome; the ﬁrst one is in the downstream
region of VZV oriS (5′CAAATGGCG-3′) and the other is within the
ORF3 promoter (5′CCCATATAT-3′) (Khalil et al., 2008, 2012, 2013).
The mutation of the YY1 site downstream of VZV oriS had no
signiﬁcant effect on VZV DNA replication or ORF62 and ORF63
transcription efﬁciency in DpnI replication and reporter gene
assays respectively although it increased the VZV growth in skin
xenografts slightly at day 21 post-infection (Khalil et al., 2012). In
contrast, mutation of the YY1 site in the ORF3 promoter inhibited
expression in reporter gene assays (Khalil et al., 2013).
In the work presented here, we investigated the role of YY1
binding sites within VZV promoters in activation of IE62-
dependent gene expression in order to better understand mechan-
isms that IE62 uses to exploit the host cell environment for
efﬁcient viral gene expression. The binding of YY1 to sites within
the putative VZV promoters of ORF10, ORF28/29 and gI was
established using EMSA and supershift assays. The mutation of
these YY1 sites ablated formation of the YY1 speciﬁc complex and
inhibited activation of these promoters. A VZV recombinant virus
with a mutation of the YY1 site in the ORF28/29 promoter was
constructed and effects on virus growth were studied. This
mutation was found to have no signiﬁcant effect on VZV replica-
tion in melanoma cells and on the ORF29 expression. On the other
hand, this mutation inhibited VZV replication in HELF signiﬁcantly
at day 5 and 6 post infection. This work suggests that the cellular
transcription factor YY1 acts as a cellular factor involved in the
IE62-mediated activation of VZV genes.
Results
Predicted YY1 binding sites within putative VZV promoters
As the ﬁrst step in studying the role of YY1 in regulation of viral
gene expression, the number of predicted YY1 binding sites in
putative VZV promoters was determined. Since there is no
degenerate consensus binding site for the YY1 protein, we used
the YY1 binding sites previously identiﬁed in the VZV genome
as the template in the bioinformatics search. These were
5′-CAAATGG-3′ in the downstream region of VZV oriS and
5′-CCCATATAT-3′ in the ORF3 promoter (Khalil et al., 2008; 2013).
The search was done with NCBI Blastn program (http://blast.ncbi.
nlm.nih.gov/Blast.cgi). In order to estimate the number of predicted
YY1 sites, we used a conservative promoter size of 200 to 300 bp
upstream from the translational start sites of the VZV genes.
Nineteen YY1 sites were identiﬁed within putative promoter
regions (Table 1). Three of the 19 promoters that had been studied
previously, including those of ORF10, ORF28/29 and gI genes were
selected to study the binding of YY1 and the inﬂuence of these
predicted YY1 binding sites on regulation of the expression of
these genes.
YY1 binds to the predicted YY1 binding sites within ORF10,
ORF28/29 and gI promoters
In the ﬁrst set of experiments, we used EMSA and supershift
assays to establish the binding of YY1 to its predicted binding sites
within VZV ORF10, ORF28/29 and gI promoters. We performed our
experiments using 40 bp duplex oligonucleotides containing wild
type and mutant YY1 sites within these promoters and nuclear
extracts from VZV infected MeWo cells. 30 bp duplex oligonucleo-
tides containing the origin binding protein (OBP) box A sequence
in the ORF62/ORF63 intergenic region was used as the nonspeciﬁc
competitor (Khalil et al., 2008). The sequence of the duplex
oligonucleotides used in the EMSA and supershift assays are listed
in Table 2.
EMSA and supershift assays using the oligonucleotides contain-
ing the predicted YY1 binding site of the ORF10 promoter revealed
multiple complexes including two major faster migrating com-
plexes and several minor slowly migrating complexes (Fig. 1A).
Antibody supershift assays were then performed to assess the
binding of the YY1 cellular transcription factors to this site. The
anti-YY1 antibody supershifted one of the minor complexes
formed (Fig. 1A).
In the next series of experiments, EMSAs were performed using
oligonucleotides containing the mutation in the YY1 binding site
of the ORF10 promoter that AliBaba2.1 and Patch programs (http://
www.gene-regulation.com/pub/programs.html; Biobase) pre-
dicted to inhibit the binding of YY1. The mutant probe has a
substitution of the CC residues with AA in the YY1 binding site.
As shown in Fig. 1B, this mutation inhibited the formation of the
identiﬁed YY1 complex and also affected the formation of some of
the major complexes suggesting that these complexes may need
the presence of the YY1 binding site.
To test the speciﬁcity of the formation of the YY1 containing
complex with ORF10 containing nucleotides, competition EMSA
experiments were done using unlabeled oligonucleotides contain-
ing the YY1 binding site of the ORF10 promoter as the speciﬁc
competitor and a 30-bp oligonucleotides containing the origin
binding protein (OBP) box A sequence described above. As shown
in Fig. 1C, the cold speciﬁc competitor efﬁciently competed away
the formation of the YY1 containing complex and some major
complexes, while the presence of the nonspeciﬁc competitor had
no effect on the shift pattern. These experiments indicated that
cellular transcription factor YY1 binds speciﬁcally to the ORF10
promoter element.
Table 1
List of the VZV promoters containing predicted YY1 binding site.
VZV gene No. of YY1 site YY1 site sequence
ORF3 1 CCCATATA
ORF4 1 AATGGG
ORF7 1 CCCATTTTT
ORF10 1 CCCCATT
ORF11 1 CCCATATA
ORF15 1 CCCCCCCATTTT
ORF28/29 1 CCCCCCATT
ORF30 1 CCCATAT
ORF35 1 AAAAATGGG
ORF42 1 CCCATTT
ORF49 1 CCCATT
ORF61 1 CCCATTT
ORF63, 70 3 CCCCCATT, CCATTTT, AAATGG
ORF67 1 CCCCATT
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Next, a similar series of experiments was carried out to detect
the binding of YY1 to the ORF28/29 promoter and to test the
speciﬁcity of this binding. Numerous complexes formed using the
YY1 site-containing oligonucleotides from the ORF28/29 promoter,
of which the major complex is the fastest migrating complex
(Fig. 2A). Antibody supershift assays were then performed to
determine the binding of the YY1 cellular transcription factors to
these sequences. The anti-YY1 antibody supershifted the major
complex (Fig. 2A).
In the next series of experiments, EMSAs were performed using
oligonucleotides containing a mutation in the YY1 binding site
predicted to inhibit the binding of YY1. The mutant probe
contained a substitution of CC residues to AA in the YY1 binding
site similar to that in the ORF10 promoter. As shown in Fig. 2B, this
mutation not only inhibited the formation of the identiﬁed YY1
complex as predicted but also enhanced the formation of minor
complexes suggesting that these factors are competing with YY1
for binding to this probe.
Next, competition EMSA experiments were done using unla-
beled 40-bp oligonucleotides containing the YY1 binding site from
the ORF28/29 promoter as the speciﬁc competitor, and the Box A
containing oligonucleotides as non-speciﬁc competitor. As shown
in Fig. 2C, the cold speciﬁc competitor not only competed away the
formation of the YY1 containing complex but also some minor
complexes, while the presence of the nonspeciﬁc competitor did
not inﬂuence the formation of any of the complexes formed with
the wild type oligonucleotides. These experiments indicated that
cellular transcription factor YY1 also binds speciﬁcally to the
ORF28/29 promoter.
Lastly, the binding of YY1 to the gI promoter was determined
using the same strategy. Several complexes formed using the
oligonucleotide containing the YY1 site of the gI promoter,
including two major slowly migrating complexes and two faster
migrating minor complexes (Fig. 3A). The presence of anti-YY1
antibody supershifted one of the minor complexes formed
(Fig. 3A).
A mutant probe containing the mutation that is predicted to
inhibit the binding of YY1 to the gI promoter sequence was next
used in EMSA assays. The probe has a substitution of the ﬁrst C in
the GC rich sequence representing the Sp1 site of the gI promoter
to G in the YY1 binding site. As shown in Fig. 3B, this mutation
disrupted the formation of the identiﬁed YY1 complex with no
signiﬁcant effect on the formation of the other complexes.
EMSA experiments were also done using unlabeled speciﬁc
competitor 40-bp oligonucleotides containing the predicted YY1
binding site of the gI promoter and the non-speciﬁc competitor
30-bp oligonucleotides containing the origin binding protein
Table 2
List and sequences of the duplex oligonucleotides used in the EMSA and supershift
assays.
Oligonucleotide Sequence
Wild Type ORF10 AGTTGCTACCAAACAAACCCCATTAGACGGCGGGTTTTGA
YY1 Mutant ORF10 AGTTGCTACCAAACAAACCAAATTAGACGGCGGGTTTTGA
Wild Type ORF28/29 GACCCTGCCAACAACCCCCCATTATTACGAGTACTTCACC
YY1 Mutant
ORF28/29
GACCCTGCCAACAACCCCAAATTATTACGAGTACTTCACC
Wild Type gI probe CTTAATACAGAGTCACGCCCCATTACAACAAGGATAAAAC
YY1 Mutant gI probe CTTAATACAGAGTCACGCCCCGTTACAACAAGGATAAAAC
Box A probe GTCCAACCACCGTTCGCACTTTCTTTCTAT
YY1 site indicated in bold. Mutated nucleotides indicated in bold italics.
Fig. 1. EMSA and supershift assays using 40 bp oligonucleotides containing the wild-type YY1 site of the ORF10 promoter. (A) Supershift assays were done in the presence of
VZV-infected cell nuclear extracts using polyclonal antibodies against YY1. (B) EMSA assays using wild type and YY1 mutant oligonucleotides. (C) EMSA and competition
assays using Box A containing oligonucleotides as non speciﬁc competitor. Lanes: FO, free oligonucleotide; I, VZV-infected nuclear extract. The positions of the YY1
containing complexes are indicated by arrows and the positions of the supershifted bands are indicated by asterisks. The numbers under the ﬁgures represent the relative
amounts of YY1 complexes, assessed by densitometry.
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(OBP) box A sequence. As shown in Fig. 3C, the cold speciﬁc
competitor efﬁciently competed away the formation of the YY1
containing complex and also the two major complexes formed,
while the presence of the nonspeciﬁc competitor had no inﬂuence
on the formation of any protein-DNA complex. These experiments
indicated the speciﬁcity of the YY1 binding to the gI promoter.
YY1 site mutations inhibited the promoter activities of ORF10,
ORF28, ORF29 and gI genes
In this set of experiments, reporter gene assays were done in
the context of VZV super-infection and with pCMV-62 transfec-
tion. We used wild type and YY1 mutant reporters to determine
the inﬂuence of the YY1 binding site mutations within the ORF10,
ORF28/29 and gI promoters on the expression levels of these
genes. The mutations in the reporters used in these experiments
are the same as those that inhibited the binding of YY1 to the YY1
binding sites in the EMSA assays. Luciferase activities obtained
from each reporter plasmid in the absence of VZV super-infection
and ORF62 transfection represent the basal levels from this
plasmid and were normalized to 1. Reporter gene activities in
the presence of VZV super-infection and ORF62 transfection were
reported as induction (n-fold) of luciferase activities in reference
to the basal activity.
The luciferase reporter of the ORF10 promoter contains the
242 bp intergenic region between ORF9 and ORF10 (Fig. 4A). The
ORF28/29 promoter reporter includes the 221 bp intergenic
region between ORF28 and ORF29 ﬂanked by Renilla luciferase
in place of the ORF28 gene and ﬁreﬂy luciferase in place of the
ORF29 gene (Fig. 5A). The gI promoter reporter includes 120
nucleotides before the translation start site of the ORF67 gene
(Fig. 7A).
The YY1 site mutation inhibited ORF10 promoter activation by
about 50-60% in the experiments done using pCMV-ORF62 trans-
fection and VZV super-infection (Fig. 4B and C). More strikingly,
the YY1 site mutations inhibited both ORF28 and ORF29 promoter
activation by about 90% in experiments done using either pCMV-
ORF62 transfection or VZV super-infection (Figs. 5 and 6). Lastly,
The YY1 site mutations inhibited gI expression in the reporter
gene assays by about 60–70% in experiments done using pCMV-
ORF62 transfection and VZV super-infection (Fig. 7B and C). These
results suggested the involvement of this YY1 site in the activation
of the ORF10, ORF28, ORF29 and gI promoters mediated by IE62 or
by VZV super-infection.
Inﬂuence of YY1 mutation on ORF28/29 promoter on VZV replication
in vitro
A VZV recombinant virus with the YY1 site mutation was
generated as described in the materials and methods section.
When the growth kinetics of pOka and the ORF28/29 promoter
mutant were evaluated in MeWo cells, titers were equivalent over
the ﬁrst three days post infection; then there was a slight
insigniﬁcant decrease in growth from day 4 to day 6 for the
mutant virus (Fig. 8A). We then looked at expression of the ORF29
protein in infected MeWo cells. This YY1 site mutation in the
Fig. 2. EMSA and supershift assays using 40 bp oligonucleotides containing the wild-type YY1 site of the ORF28/29 promoter. (A) Supershift assays were done in the
presence of VZV-infected cell nuclear extracts using polyclonal antibodies against YY1. (B) EMSA assays using wild type and YY1 mutant oligonucleotides. (C) EMSA and
competition assays using Box A containing oligonucleotides as non speciﬁc competitor. Lanes: FO, free oligonucleotide; I, VZV-infected nuclear extract. The positions of the
YY1 containing complexes are indicated by arrows and the positions of the supershifted bands are indicated by asterisks. The numbers under the ﬁgures represent the
relative amounts of YY1 complexes, assessed by densitometry.
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promoter had no signiﬁcant effect on the expression of ORF29
protein at 36 h post infection compared to ORF29 expression in
the wild type pOka at the same time point (Fig. 8B).
On the other hand, the growth kinetics of this mutant virus in
HELF cells showed signiﬁcant inhibition in virus replication at day
5 and 6 post infection (Fig. 8C).
Fig. 3. EMSA and supershift assays using 40 bp oligonucleotides containing the wild-type YY1 site of the gI promoter. (A) Supershift assays were done in the presence of
VZV-infected cell nuclear extracts using polyclonal antibodies against YY1. (B) EMSA assays using wild type and YY1 mutant oligonucleotides. (C) EMSA and competition
assays using Box A containing oligonucleotides as non speciﬁc competitor. Lanes: FO, free oligonucleotide; I, VZV-infected nuclear extract. The positions of the YY1
containing complexes are indicated by arrows and the positions of the supershifted bands are indicated by asterisks. The numbers under the ﬁgures represent the relative
amounts of YY1 complexes, assessed by densitometry.
Fig. 4. The effect of YY1 site mutation on ORF10 gene expression. (A) The nucleotide sequence of the ORF9-ORF10 intergenic region. The YY1 site is boxed. The USF site
reported to be important for ORF10 expression is underlined. (B and C) The results of triplicate assays assessing the effects of the presence of the YY1 site mutation in the
ORF10 promoter on the expression levels of the ﬁreﬂy luciferase reporter in the context of (B) pCMV-ORF62 transfection and (C) VZV super-infection. The promoter activities
resulting from the presence of transfected ORF62 or VZV super-infection are reported as induction (n-fold) of luciferase activity over basal (without ORF62 transfection or
VZV super-infection respectively). Statistical signiﬁcance was determined by a one-way ANOVA analysis of variance followed by Tukey's post hoc test. Error bars indicate
standard error.
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Discussion
Like other herpesviruses, the VZV genome does not encode any
RNA polymerase function or gene alternative to the TATA-binding
protein (TBP) in binding to the TATA sites within the VZV
promoters (Ruyechan et al., 2003; Ruyechan, 2010). This suggests
that the basal cellular transcription machinery is required for viral
gene expression. Most VZV promoters require TATA-elements for
their expression (Ruyechan et al., 2003) with the exception of the
ORF3 and ORF10 promoters which have been shown to be
expressed in the absence of any functional TATA box sites (Khalil
et al., 2013; Che et al., 2007). All of the VZV promoters studied to
date also contain predicted binding sites for cellular transcription
factors including Sp1, USF and ATF. Several reports have veriﬁed
that these factors contribute to expression of VZV genes both
in vitro and in vivo (Berarducci et al., 2007; Che et al., 2007; Ito et al.,
2003; Meier et al., 1994; Narayanan et al., 2005; Peng et al., 2003;
Rahaus and Wolff, 2003; Rahaus et al., 2003; Wang et al., 2009; Yang
et al., 2004).
IE62 is the major VZV trans-activator, the product of ORF62 and
its complement ORF71. The deletion of both copies of ORF62 and
ORF71 blocked VZV replication (Sato et al., 2003). IE62 has been
shown to interact physically with cellular factors Sp1 and USF, as
well as TBP (Peng et al., 2003; Rahaus et al., 2003; Perera 2000).
IE62 has also been shown to interact with the human mediator
complex through its N-terminal acidic activation domain (Yang
et al., 2008; Yamamoto et al., 2009). These physical interactions
have been shown to be important for the expression of some VZV
promoters in reporter gene assays. Mutations of the binding sites
for these cellular factors in ORF61 and ORF10 promoters have been
shown to inhibit VZV replication in skin xenografts (Wang et al.,
2009; Che et al., 2007).
YY1 is a zinc-ﬁnger protein that has the ability to repress
and activate gene transcription in several mammalian viruses
Fig. 5. The effect of YY1 site mutation in the ORF28/29 promoter on ORF28 gene expression. (A) The nucleotide sequence of the ORF28-ORF29 intergenic region. The YY1 site
is boxed. The USF site reported to be important for ORF28 and ORF29 expression is underlined. The TATA boxes appear in bold italics. (B and C) The results of triplicate assays
assessing the effects of the presence of the YY1 site mutation in the ORF28 promoter on the expression levels of the Renilla luciferase reporter in the context of (B) pCMV-
ORF62 transfection and (C) VZV super-infection. The promoter activities resulting from the presence of transfected ORF62 or VZV super-infection are reported as induction
(n-fold) of luciferase activity over basal (without ORF62 transfection or VZV super-infection respectively). Statistical signiﬁcance was determined by a one-way ANOVA
analysis of variance followed by Tukey's post hoc test. Error bars indicate standard error.
Fig. 6. The effect of YY1 site mutation in the ORF28/29 promoter on ORF29 gene expression. (A and B) The results of triplicate assays assessing the effects of the presence of
the YY1 site mutation in the ORF29 promoter on the expression levels of the ﬁreﬂy luciferase reporter in the context of (A) pCMV-ORF62 transfection and (B) VZV super-
infection. The promoter activities resulting from the presence of transfected ORF62 or VZV super-infection are reported as induction (n-fold) of luciferase activity over basal
(without ORF62 transfection or VZV super-infection respectively). Statistical signiﬁcance was determined by a one-way ANOVA analysis of variance followed by Tukey's post
hoc test. Error bars indicate standard error.
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including adeno-associated virus, human papillomavirus, parvo-
virus B19, HSV-1 and Moloney murine leukemia virus (Lee et al.,
1992, 1998; Pajunk et al., 1997; Bauknecht and Shi 1998). We had
previously identiﬁed two binding sites for YY1 in the VZV genome.
Mutation of one these YY1 sites in the downstream region of VZV
oriS had no signiﬁcant effect on either origin-dependent DNA
replication or expression of the ORF62 and ORF63 ﬂanking genes.
However, mutation of this YY1 site in a VZV recombinant virus
was associated with an increase in VZV genome copies in MeWo
cells and viral replication in skin xenografts (Khalil et al., 2008;
2012). Mutation of the YY1 site in the ORF3 promoter inhibited
ORF3 expression in reporter gene assays (Khalil et al., 2013).
In this study, we identiﬁed additional putative YY1 sites and
expanded our analysis to the role played by YY1 in IE62 mediated
activation of VZV gene expression. We investigated binding of YY1
to the promoters of VZV ORF10, ORF28/29 and gI genes. These
Fig. 7. The effect of YY1 site mutation in the gI promoter on gI gene expression. (A) The nucleotide sequence of the gI promoter. The YY1 site is boxed. The USF and the Sp1
sites reported to be important for gI expression is underlined. The TATA box appears in bold italics. (B and C) The results of triplicate assays assessing the effects of the
presence of the YY1 site mutation in the gI promoter on the expression levels of the ﬁreﬂy luciferase reporter in the context of (B) pCMV-ORF62 transfection and (C) VZV
super-infection. The promoter activities resulting from the presence of transfected ORF62 or VZV super-infection are reported as induction (n-fold) of luciferase activity over
basal (without ORF62 transfection or VZV super-infection respectively). Statistical signiﬁcance was determined by a one-way ANOVA analysis of variance followed by Tukey's
post hoc test. Error bars indicate standard error.
Fig. 8. The effect of VZV pOka-YY1 site mutation in the ORF28/29 promoter on VZV replication. (A) Growth kinetics of pOka and pOka-YY1 mutant virus in MeWo cells. Cells
were inoculated at 103 PFU/ml with wild type and mutant viruses and infectious virus yields were determined for 6 days after inoculation. (B) Effect of YY1 site mutation on
ORF29 expression levels in MeWo cells during VZV infection. Western blot analyses show the expression levels of ORF29 and α-tubulin at 36 h post-infection. α-tubulin was
used as a loading control in the experiments. The blots were scanned by densitometry to obtain quantitative data (in triplicate). Statistical signiﬁcance was determined by a
one-way ANOVA analysis of variance followed by Tukey's post hoc test. (C) Growth kinetics of pOka and pOka-YY1 mutant virus in HELF cells. Cells were inoculated at 103
PFU/ml with wild type and mutant viruses and infectious virus yields were determined for 6 days after inoculation.
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three promoters are analyzed previously and selected for the
presence of the postulated YY1 binding sites within the sequences
that had been shown to be required for the activation of the
promoter (Che et al., 2007; Yang et al., 2004; Peng et al., 2003).
The mutation of these YY1 binding sites not only inhibited the
formation of the YY1 complexes but also inhibited expression in
reporter gene assays in the context of IE62 transfection and VZV
superinfection. These results suggested a possible role for YY1 in
lytic gene expression and possibly also in VZV replication.
The mutation of the YY1 binding site inhibited the expression
from ORF28/29 promoter by about 90%, showing that this YY1 site
is required for the expression of these genes. Previous analysis of
this intergenic region showed the presence of a USF binding site
which appeared to be required for activity from these promoters
(Yang et al., 2004). The presence of this USF site; however, failed to
compensate for the absence of the YY1 binding site.
On the other hand, the mutation of the YY1 binding site in
ORF10 and gI promoters inhibited the expression of these genes by
only about 60–70%. Analysis of the ORF10 promoter showed the
presence of an important USF site and previous analysis of the gI
promoter had shown the presence of an Sp1 site adjacent to the
YY1 binding site (Che et al., 2007; Peng et al., 2003). It is quite
possible that either or both of these factors could partially
compensate for the absence of the YY1 binding sites in these
promoters.
The physical interaction between IE62 and YY1 was tested
using GST-pulldown assays (data not shown). This interaction
requires the same domain of IE62 (aa 1-299) that was shown to
be required for the interaction of IE62 with Sp1 and USF (Peng
et al., 2003; Rahaus et al., 2003). Both IE62 and YY1 have been
shown to physically interact with Sp1 (Peng et al., 2003; Lee et al.,
1993; Seto et al., 1993; Shi et al., 1997), raising the possibility that
binding could occur between YY1 and IE62 at their respective sites
in the VZV promoters, either directly or bridged by the presence of
Sp1. This physical interaction may be important for the recruit-
ment of the basal cellular transcription machinery at the VZV
promoters or perhaps for stabilizing its involvement.
A recombinant virus carrying the YY1 mutation in the ORF28/
29 promoter grew as well as the wild type virus in melanoma cells,
with similar expression level of the ORF29 protein. On the other
hand, this mutation signiﬁcantly inhibited virus replication in
HELF cells at later times of infection (day 5 and 6 postinfection).
This moderate inhibition with this mutation in HELF cells might
well be attributed to the involvement of the ORF29 protein in the
origin-dependent DNA replication process (Khalil et al., 2011). We
have shown in our previous work that ORF29 protein binds to a
sequence downstream of VZV oriS in VZV infected cells. The
binding of ORF29 protein to this sequence downregulated oriS
dependent DNA replication and enhanced ORF62 and ORF63
expression. The mutation of the YY1 site in the ORF28/29 promo-
ter inhibited ORF29 expression signiﬁcantly as shown in reporter
gene assays. This decrease in ORF29 expression should thus lead to
some upregulation of oriS dependent DNA replication, leading to a
possible increase in the number of virus genome copies in cells
infected with the mutant recombinant viruses. This effect might
moderate or mask the effect of ORF29 transcription downregula-
tion due to the YY1 mutation. The study of this mutant virus
inﬂuence over VZV replication in other cells and tissues will be a
point of interest in the future, since we have clearly shown
differences in response in two separate human cell lines (MeWo
and HELF). Also, generation of viral mutants to test the inﬂuence of
mutations in YY1 sites in other promoters (e.g. ORF10 and gI) will
be important future point for more extensive evaluation of the role
of YY1 in the VZV replication.
The study of cellular factors inﬂuencing VZV replication is
important for developing antiviral drug strategies, through
generation of inhibitors to interfere with the functions of these
factors leading to inhibition of virus replication. Such studies are
also essential to a better understanding how the lytic and latent
phases of virus replication are controlled. In this report, we have
established the importance of the cellular factor YY1, in mediating
VZV IE62 transcriptional activation, and in controlling viral gene
expression.
Materials and methods
Cells and viruses
MeWo cells, a human melanoma cell line, and HELF cells, a
human embryonic lung ﬁbroblast cell line, were grown in Eagle's
minimal essential medium supplemented with 10% fetal bovine
serum (Spengler et al., 2000). VZV strains MSP and pOka were
propagated in MeWo cell and HELF cell monolayers as described
by Lynch et al. (2002) and Peng et al. (2003).
Nuclear and whole cell lysate preparation and immunoblot analysis
Nuclear extracts of VZV infected MeWo cells were prepared as
previously described (Lynch et al., 2002). MeWo cells were
incubated in buffer A (10 mM HEPES, pH 7.9, 1.5 mM MgCl2,
10 mM KCl, 0.5 mM dithiothreitol) at 4 1C for 15 min to lyse the
cells and release the cytoplasmic fraction. After centrifugation, the
crude nuclear pellet was incubated on ice in buffer C (20 mM
HEPES, pH 7.9, 25% (v/v) glycerol, 0.42 M NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl ﬂuoride, 0.5 mM
dithiothreitol). After centrifugation, the nuclear extract was dia-
lyzed against buffer D (20 mM HEPES, pH 7.9, 20% (v/v) glycerol,
0.1 M KCl, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl ﬂuoride,
0.5 mM dithiothreitol).
Whole cell lysates of VZV infected MeWo cells were prepared in
lysis buffer (50 mM Tris–HCl, pH 7.5, 0.15 M NaCl, 1 mM EDTA, 0.1%
Triton X-100 and protease inhibitor cocktail (Roche, Mannheim,
GE) added per the manufacturer's instructions) and analyzed for
ORF29 by immunoblot. Rabbit polyclonal antisera against the
C-terminus half of the ORF29 protein by immunoblot (10% SDS-
PAGE) using rabbit polyclonal antibody against the C-terminus of
ORF29 protein (Peng et al., 2003; Kinchington et al., 1988). Mouse
monoclonal antibody against α-tubulin was obtained from Sigma-
Aldrich (St. Louis, MO). Quantiﬁcation of the relative amounts of
ORF29 and α-tubulin was done using a BioRad GS700 Imaging
Densitometer (BioRad Hercules, CA). Statistical signiﬁcance was
determined by one-way ANOVA analysis of variance followed by
Tukey's post hoc test.
Plasmids
The luciferase reporter plasmids containing the ORF10, ORF28/
29 and gI promoters were constructed as described (Che et al.,
2007; Yang et al., 2004; White et al., 2010). The wild type ORF10-
Luc was constructed by inserting a 242 bp intergenic region
between ORF9 and ORF10 into the pGL3 basic vector ﬂanked by
ﬁreﬂy luciferase. The wild type R28/29F was constructed by
inserting a 221 bp intergenic region between ORF28 and ORF29
into the basic pGL2 luciferase vector containing the Renilla and
ﬁreﬂy luciferase reporters. The wild type gI-Luc was constructed
by inserting the gI (VZV ORF67) promoter sequence into the pGL2
basic vector ﬂanked by ﬁreﬂy luciferase.
The plasmids containing the YY1 site speciﬁc mutations within
the ORF10, ORF28/29 and gI promoters were generated from the
wild type plasmids containing the wild type promoter sequences
using the QuikChange Site-Directed Mutagenesis Kit (Stratagene,
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LaJolla, CA). The primer sets for these mutations were: ORF10
promoter YY1 site: 5′-TCAGTTGCTACCAAACAAACCAAATTAGACGG-
CGGGTTTTGATAA-3′ and 5′-TTATCAAAACCCGCCGTCTAATTTGG-
TTTGTTTGGTAGCAACTGA-3′; ORF28/29 promoter YY1 site: 5′-TT-
GACCCTGCCAACAACCCCAAATTATTACGAGT ACTTCACCAAA-3′ and
5′-TTTGGTGAAGTACTCGTAATAATTTGGGGTTGTTGGC AGGGTCAA-
3′; and gI promoter YY1 site: 5′-AACTTAATACAGAGTCACGC-
CCCGTT ACAACAAGGATAAAACACG-3′ and 5′-CGTGTTTTATCC-
TTGTTGTAACGGGGCGT GACTCTGTATTAAGTT-3′. The mutated
nucleotides are indicated in bold. All primers were synthesized
by IDT (Coralville, IA). The mutations were veriﬁed by sequencing
at the Roswell Park Cancer Institute sequencing facility, Buffalo NY.
The pCMV62 plasmid expressing ORF62 under the control of
the cytomegalovirus immediate-early (IE) promoter has been
described previously (Perera et al., 1992a, 1992b and 1993).
Reporter gene assays
Luciferase reporter gene assay experiments were performed in
MeWo cells as previously described (Yang et al., 2004). Transfec-
tions were performed using 12-well plates. 2105 MeWo cells
were seeded in each well 24 h before transfection. Cells were
transfected with one microgram of each reporter vector using
Lipofectamine reagent (Invitrogen, Carlsbad, CA), along with 5 ng
of pEF1α-RL plasmid (Promega, Madison, WI) for ORF10 and gI
promoter experiments or 0.4 μg of β-galactosidase (β-Gal)-expres-
sing plasmid (Invitrogen, Carlsbad, CA) for ORF28/29 promoter
experiments as a control of transfection efﬁciency. The cells were
super infected with VZV MSP 24 h post transfection 0.4 infected
cells per 1 uninfected cell.
In the experiments done in the presence of IE62, the reporter
plasmids were co-transfected with 5 ng of pCMV-ORF62 expres-
sing plasmids. Dual luciferase activities were normalized to the
Renilla luciferase activities or β-Gal. pcDNA was transfected along
with the pCMV62 plasmid to equalize the amounts of both total
DNA and the promoter construct in each set of transfections.
The cells were lysed 48 h post transfection or super-infection in
250 μl of lysis buffer (50 mM HEPES, pH 7.4, 250 mM NaCl, 1% NP-
40, 1 mM EDTA). Control experiments without transfection of
pCMV-ORF62 or VZV infection were done for each plasmid to
determine basal expression levels. Dual-luciferase assays were
performed according to the manufacturer's instruction. Transfec-
tion experiments were repeated at least three times.
EMSA and supershift analyses
A 40 bp oligonucleotide probes (IDT, Coralville, IA) containing
wild type and mutant YY1 binding sites were used in electro-
phoretic mobility shift assays (EMSAs). Probes were end labeled
with ATP [α-32P] using T4 kinase (Invitrogen, Carlsbad, CA). One
hundred femtomoles of the 40 bp labeled probes containing either
the wild type or the mutant sequences (1105 dpm) were
incubated with 15 mg of VZV infected MeWo cell nuclear extract
in a 10 ml reaction mixture in binding buffer: 40 mM HEPES, pH
7.9, 100 mM NaCl, 10 mM MgCl2, 200 mg/ml bovine serum albumin
(BSA), 12% glycerol, 0.05% NP-40, 1 mM dithiothreitol, and 3 mg
poly (dI.dC). The samples were analyzed by electrophoresis on a
5% polyacrylamide (37.5:1 acrylamide/bisacrylamide) gel followed
by autoradiography. In competition assays, the ratio of cold probe
to labeled probe was 100:1. In the supershift assays, rabbit
polyclonal YY1 antiserum, generously supplied by Dr. Te-Chung
Lee (University at Buffalo) was added in 2 ml (YY1) aliquots to
reaction mixtures before the addition of the labeled probe to the
nuclear extract-antibody mixture. Quantiﬁcation of the relative
amounts of YY1 complexes was done using a BioRad GS700
Imaging Densitometer (BioRad Hercules, CA).
Generation and growth kinetics of a pOka recombinant virus with
mutation in the YY1 site of the ORF28/29 promoter
Recombinant virus was produced using the self-excisable
pOka-BAC (pOka—parental Oka) as described previously (Oliver
et al., 2009; Tischer et al., 2007). The mutagenic primers for the
YY1 site were: ORF28/29 mut-F 5′-ACAGACTGGGTTTTGGGTGGT-
CATTTGACCCTGCCAACAA CCCCAAATTATTACGAGTACTTCACAGGA-
TGACGACGATAAGTAGGG-3′ and ORF28/29 mut-R 5′-AGTCTTCT-
GAGTATTTTCCATTTTGGTGAAGTACTCGTAAT AATTTGGGGTTGTTG-
GCAGGGTCACAACCAATTAACCAATTCTGATTAG-3′. The changed
nucleotides are indicated in bold italics. The primers were used
to amplify the Kanr gene from the pKan-EP-S vector using
Accuprime Pfx polymerase (Invitrogen, Carlsbad, CA). The PCR
products were cloned into pCR4-TOPO after the addition of
adenosine overhangs using recombinant Taq polymerase (Invitro-
gen, Carlsbad, CA). Clones were sequenced to determine that the
VZV speciﬁc sequences contained the desired changes and did not
have any unexpected deletions or substitutions. The Kanr cassette
ﬂanked with the VZV sequences were ampliﬁed from the pCR4
vectors using short primers (ORF28/29 promoter-F PCR 5′-ACA-
GACTGGGTTTTGGGTGGTCATTTGACC-3′ and ORF28/29 promoter-R
PCR. 5′-AGTCTTCTGAGTATTTTCCATTTTGGTG-3′ to generate high
yields of the PCR product. PCR products were gel puriﬁed (QIA-
GEN, Inc., Valencia, CA) and then used for recombination. The
recombination steps were screened by PCR for the addition and
subsequent removal of the Kanr cassette. Positive clones were
puriﬁed using a Large-construct kit (QIAGEN, Inc., Valencia, CA).
All puriﬁed BACs were digested with HindIII to ensure the
expected DNA fragments were present and sequenced to verify
the changed nucleotides.
Transfections were done as previously described (Niizuma
et al., 2003). DNA was extracted from infected cells using DNazol
(Invitrogen) and used as a template for PCR using the following
primers PCR ORF28-29F 5′-TAAGTGTACCGACGTGA ACC-3′ and PCR
ORF28-29R 5′-ACCCGTAGTGCGTGCTCCAG-3′ and the mutation in
the ORF28/29 promoter was veriﬁed by sequencing using the
above PCR primers (Quintarabio. Berkeley, CA). Excision of the
Mini F vector from the Bac-derived virus was done as previously
described (Oliver et al., 2009).
The replication kinetics of recombinant viruses was assessed by
an infectious focus assay with immunostaining to detect plaques
as previously described (Chaudhuri et al., 2008; Moffat et al.,
1995). Brieﬂy, 6-well assay plates and 24-well titer plates were
seeded with MeWo and HELF cells. Assay plates were incubated
for variable times, and several dilutions of the samples were taken
for infectious focus assay. Titer plates were incubated for 4 days
then ﬁxed with 4% paraformaldehyde for immunohistochemical
staining using anti-VZV monoclonal antibody (Meridian). Statisti-
cal differences in growth kinetics were determined by Student's
t test.
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